FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicalsPatients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeksEBGLYSS delivers long-lasting efficacy for patients through one year of treatment with a monthly maintenance doseINDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Admini ...